anti-GLP-1/PCSK9 fusion antibody (MedImmune)

N/A

Report date: 2026/05/12 20:00:17

Base Information

Drug Nameanti-GLP-1/PCSK9 fusion antibody (MedImmune)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionLDL cholesterol modulatorsAnti-Glucagon-like peptide 1 receptorAnti-Proprotein convertase subtilisin kexin type 9
TargetsLDL cholesterolGlucagon-like peptide 1 receptorProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesMedimmune Llc
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A